000			02125 a2200613 4500
005			20250516222603.0
264		0	_c20150615
008			201506s 0 0 eng d
022			_a2567-689X
024	7		_a10.1160/TH13-10-0891 _2doi
040			_aNLM _beng _cNLM
100	1		_aGurbel, P A
245	0	0	_aThe effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease. _h[electronic resource]
260			_bThrombosis and haemostasis _cSep 2014
300			_a589-97 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase I; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
650	0	4	_aAged
650	0	4	_aClinical Protocols
650	0	4	_aClopidogrel
650	0	4	_aCoronary Artery Disease _xdrug therapy
650	0	4	_aCytochrome P-450 CYP2C19 _xgenetics
650	0	4	_aFemale
650	0	4	_aGenotype
650	0	4	_aHumans
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aPhenotype
650	0	4	_aPiperazines _xadministration & dosage
650	0	4	_aPlatelet Aggregation _xdrug effects
650	0	4	_aPlatelet Aggregation Inhibitors _xadministration & dosage
650	0	4	_aPolymorphism, Genetic
650	0	4	_aPrasugrel Hydrochloride
650	0	4	_aThiophenes _xadministration & dosage
650	0	4	_aTiclopidine _xadministration & dosage
650	0	4	_aTreatment Outcome
700	1		_aBergmeijer, T O
700	1		_aTantry, U S
700	1		_aten Berg, J M
700	1		_aAngiolillo, D J
700	1		_aJames, S
700	1		_aLindahl, T L
700	1		_aSvensson, P
700	1		_aJakubowski, J A
700	1		_aBrown, P B
700	1		_aDuvvuru, S
700	1		_aSundseth, S
700	1		_aWalker, J R
700	1		_aSmall, D
700	1		_aMoser, B A
700	1		_aWinters, K J
700	1		_aErlinge, D
773	0		_tThrombosis and haemostasis _gvol. 112 _gno. 3 _gp. 589-97
856	4	0	_uhttps://doi.org/10.1160/TH13-10-0891 _zAvailable from publisher's website
999			_c23993696 _d23993696